Skip to content

EBITDA at other companies

Dyne Therapeutics, Inc. logo
Dyne Therapeutics, Inc.DYN
-$124.73M-2.3%
Taysha Gene Therapies, Inc. logo
Taysha Gene Therapies, Inc.TSHA
-$43.19M-104%
Edgewise Therapeutics, Inc. logo
Edgewise Therapeutics, Inc.EWTX
-$53.58M-17.9%
uniQure logo
uniQureQURE
-$42.76M-22.9%
Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX
Insmed logo
InsmedINSM

Other financials

Income statement

See full
Revenue$2.0M-40.6%
Operating income-$57.3M-43.1%
Net income-$56.7M-44.4%
EPS (diluted)-$0.52+11.9%

Balance sheet

See full
Cash & equivalents$297.1M+41.1%
Total debt$20.7M-12.5%
Total equity$374.1M+27.1%
Total assets$422.9M+23.0%

Cash flow

See full
Operating cash flow-$47.2M-48.3%
CapEx$165.0K+31.0%
Free cash flow-$47.4M-48.2%

Valuation

See full
Market cap$910.66M+135%
Enterprise value$634.23M+223%
P/S112.5×-10.3×

Profitability

See full
Operating margin-1,315.2%-4,060pp
Net margin-1,062.3%-251,151pp
FCF margin-1,247.7%-9,569pp

Returns & leverage

See full
Return on equity-57.4%+2.2pp
Debt / equity0.1×0.0×
Current ratio13.1×+2.2×

Where this comes from

Calculated from Solid Biosciences Inc.’s reported figures.

$57.3Mebit+
$395.0KDepreciation Depletion & Amortization
=-$56.91M

The official record: Solid Biosciences Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Solid Biosciences Inc.'s ebitda.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Solid Biosciences Inc.'s EBITDA?
Solid Biosciences Inc. (SLDB) reported EBITDA of -$56.91M in Q1 2026.
How has Solid Biosciences Inc.'s EBITDA changed year-over-year?
Solid Biosciences Inc.'s EBITDA decreased by 43.6% year-over-year, from -$39.65M to -$56.91M.
What is the long-term trend for Solid Biosciences Inc.'s EBITDA?
Over 4 years (2021 to 2025), Solid Biosciences Inc.'s EBITDA has grown at a 26.5% compound annual growth rate (CAGR), from -$69.29M to -$177.57M.
What does EBITDA mean?
Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.